Search

A 79-year-old man with adult T-cell leukaemia/lymphoma (ATL) showed lack of efficacy to multiple treatments including mogamulizumab, cyclophosphamide, doxorubicin, prednisolone, vincristine, carboplatin, etoposide, irinotecan, gemcitabine, and dexamethasone. Despite various courses of chemotherapy and radiation therapy, his disease rapidly progressed, leading to worsened respiratory status. Ultimately, the patient responded positively to valemetostat treatment, resulting in stable disease and improved respiratory function after initial complications. The man remained on valemetostat treatment for 5 months with notable improvements in pleural effusion and laboratory parameters. [Extracted from the article]

A 59-year-old woman with diffuse large B-cell lymphoma exhibited lack of efficacy during treatment with multiple drugs, including bendamustine, cyclophosphamide, and rituximab. Following obinutuzumab treatment, she developed thrombocytopenia. Despite various treatment regimens, including CAR T-cell therapy, the woman's lymphoma progressed, but eventually stabilized after receiving cytokine-induced-killer-cell therapy and obinutuzumab. [Extracted from the article]

A 61-year-old woman with B/myeloid mixed phenotype acute leukaemia (MPAL) showed lack of efficacy to multiple chemotherapy regimens. She also experienced grade-I cytokine release syndrome during treatment with anti-CD19-CAR-transduced-T-cells. Despite receiving supportive care and achieving complete remission with the CAR-T cell therapy, she ultimately passed away due to disease relapse after 8 months. [Extracted from the article]

A 41-year-old woman with adrenocortical carcinoma and hypoglycaemia showed lack of efficacy to various treatments, including etoposide, doxorubicin, cisplatin, dexamethasone, hydrocortisone, prednisolone, octreotide, and everolimus. Despite initial regression of her tumour with chemotherapy, her condition worsened, and she ultimately passed away due to adrenocortical carcinoma. The patient's resistance to high doses of glucocorticoids, growth hormone, and octreotide indicated lack of efficacy to these therapies, highlighting the challenges in managing her complex medical condition. [Extracted from the article]

The article from Reactions Weekly discusses two case reports of elderly patients with chronic lymphocytic leukaemia (CLL) who exhibited lack of efficacy during treatment with various drugs. In the first case, a woman with CLL did not respond to daratumumab and eventually died due to disease progression. In the second case, a patient with CLL and breast cancer experienced worsening clinical condition despite treatment with multiple drugs, leading to death from disease progression. [Extracted from the article]

A cohort study analyzed the use of etoposide and catequentinib in treating non-small cell lung cancer (NSCLC) in 46 patients. One patient developed grade 2 haemoptysis while on this treatment regimen, leading to the withdrawal of both medications. The patient's condition improved after receiving haemostatic drugs. [Extracted from the article]

A man in his 20s with T-cell lymphoblastic lymphoma exhibited lack of efficacy during treatment with various antineoplastic drugs. Despite receiving multiple medications, including dasatinib, his condition worsened, leading to complications such as eosinophilic myocarditis and hospital-acquired pneumonia. Ultimately, the patient's family opted for conservative therapy and palliative care, and he passed away after 3 weeks of hospitalization due to the progression of his lymphoma and associated complications. [Extracted from the article]

This article from Reactions Weekly discusses two cases of cardiac impairment in patients with Ewing's sarcoma who were undergoing treatment with cyclophosphamide, doxorubicin, etoposide, ifosfamide, and vincristine. The patients developed adverse effects at 39 and 42 weeks into their treatment, leading to the discontinuation of chemotherapy. Despite this, both patients achieved complete remission of Ewing's sarcoma. [Extracted from the article]

A case report published in Reactions Weekly describes a 54-year-old woman with adult T-cell lymphoma/leukemia who experienced a lack of efficacy during treatment with cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone, and methotrexate. Despite receiving these medications, the patient's tumor progressed and she developed peritoneal carcinomatosis. She was later diagnosed with myocarditis and due to her deteriorating condition and poor prognosis, she was transitioned to palliative care. This case highlights the challenges in treating this type of cancer and the need for alternative therapeutic options. [Extracted from the article]

A 51-year-old man with stage 3C small-cell lung cancer (SCLC) developed anaemia while being treated with cisplatin and etoposide. He also experienced lack of efficacy during treatment with carboplatin, etoposide, and durvalumab. Despite receiving durvalumab, etoposide, and carboplatin, the patient had progressive disease with multiple metastases. In January 2024, durvalumab was stopped and the patient began receiving seven cycles of etoposide and cisplatin. His hemoglobin level dropped during the third series, leading to the conclusion that etoposide and carboplatin induced anaemia. Treatment with epoetin-alfa was initiated in March 2024, resulting in an improvement in anaemia. The patient's hemoglobin level continued to improve with subsequent cycles, and paclitaxel was started in June 2024 based on further clinical investigation. [Extracted from the article]

In a single-center study involving 134 children with acute promyelocytic leukemia (APL), a case was described where a child exhibited a lack of efficacy with tretinoin and arsenic-trioxide treatment. The child had previously received a different treatment protocol and started receiving tretinoin and arsenic-trioxide for APL. Unfortunately, the child was resistant to these treatments and ultimately died due to the progression of APL. [Extracted from the article]

A 66-year-old woman with histiocytic sarcoma experienced severe myelosuppression and lack of efficacy during treatment with ifosfamide, mitoxantrone, vincristine, etoposide, and prednisone. She initially received a poly-chemotherapy induction regimen followed by consolidation therapy with high-dose chemotherapy. However, she developed severe myelosuppression and showed no improvement in her condition. She was then treated with pembrolizumab in combination with a GDP regimen, which resulted in an effective response. After experiencing severe thrombocytopenia, she was treated with sintilimab and thalidomide and remained symptom-free in complete remission for over 4 years. [Extracted from the article]

In a retrospective study, a woman with primary mediastinal B-cell lymphoma (PMBCL) developed trachea-oesophageal fistula, recurrent aspiration pneumonia, and severe cachexia during treatment with rituximab, etoposide, doxorubicin, vincristine, prednisone, and cyclophosphamide while pregnant. The woman required PEG tube feeding and had an elective C-section at 33 weeks, but the outcome of the pregnancy was not stated. [Extracted from the article]

A 66-year-old woman with gray zone lymphoma experienced lack of efficacy during treatment with multiple drugs, including rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, oxaliplatin, brentuximab vedotin, ifosfamide, carboplatin, and etoposide. Despite receiving various therapies, her lymphoma remained refractory. However, after being treated with pembrolizumab, she achieved a complete response without any relapse of the lymphoma. [Extracted from the article]

A 62-year-old woman with myeloproliferative syndrome received multiple drugs, including cyclophosphamide, vindesine, doxorubicin-liposomal, etoposide, prednisone, venetoclax, azacitidine, tucidinostat, and dasatinib. Despite the treatment, her condition worsened, and she developed enlarged lymph nodes and splenic enlargement. Her treatment was adjusted, but the disease progressed to acute myeloid leukemia (AML). Unfortunately, due to economic constraints, she was unable to continue treatment and eventually died from a pulmonary infection. [Extracted from the article]

This article presents three case reports of patients with Philadelphia positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) or chronic myeloid leukemia (CML) lymphoid blast crisis who experienced grade 4 skin toxicity and lack of efficacy with various drug treatments. The first patient developed skin toxicity after treatment with ponatinib and showed no improvement with dasatinib and other chemotherapy drugs. The second patient also had no response to ponatinib and the BFM 2002 chemotherapy regimen. The third patient did not respond to ponatinib and the BFM 2002 chemotherapy regimen for CML lymphoid blast crisis. All three patients showed improvement after receiving alternative treatments and underwent haploidentical transplant. [Extracted from the article]

A 23-year-old woman with Hodgkin's lymphoma experienced a lack of efficacy during treatment with multiple antineoplastic drugs. She initially received the ABVD regimen, followed by the DHAP and ICE regimens, but her disease continued to progress. Radiotherapy also failed to halt the progression. She then underwent treatment with bendamustine, but her disease continued to worsen. Currently, she is receiving brentuximab vedotin. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of carboplatin, cyclophosphamide, doxorubicin, etoposide, and vincristine in the treatment of malignant extrarenal rhabdoid tumor (MERT) in a neonate girl. The girl was diagnosed with MERT shortly after birth and received treatment with the aforementioned drugs. However, the tumor rapidly progressed, leading to respiratory distress and ultimately death. This case highlights the need for further research and alternative treatment options for MERT. [Extracted from the article]

A 13-year-old boy experienced a lack of efficacy during his treatment for an intracranial non-germinomatous germ cell tumor. He received carboplatin, ifosfamide, and etoposide, but after two cycles of chemotherapy, an MRI showed an increase in tumor size. The tumor was surgically removed and histology revealed that it had transformed into embryonal rhabdomyosarcoma. Molecular characterization confirmed the initial diagnosis, and the boy planned to undergo six chemotherapy cycles followed by high-dose craniospinal radiation. [Extracted from the article]

An 18-year-old boy with pilocytic astrocytoma experienced lack of efficacy during treatment with carboplatin and etoposide. The boy had a solid-cystic lesion in the pineal region and underwent surgery to remove it. However, after three years, disease progression was observed despite receiving carboplatin and etoposide. The boy underwent further surgeries and radiation therapy, but disease progression continued. In January 2020, he started combination therapy with bevacizumab and irinotecan, which improved his condition. As of January 2023, he had stable disease with no symptomatic recurrence. [Extracted from the article]

A case report published in Reactions Weekly describes a child with pediatric Low Grade Glioma (pLGGs) who exhibited lack of efficacy during treatment with cisplatin, carboplatin, and etoposide. The child was enrolled in a study and received treatment with carboplatin, cisplatin, and etoposide according to a modified regimen. However, despite these treatments, the child experienced disease progression and ultimately died due to low grade glioma progression. [Extracted from the article]

A 27-year-old woman developed isolated hyperphosphataemia during chemotherapy for acute myeloid leukemia. She presented with thrombocytopenia and leukopenia and was diagnosed with acute myeloid leukemia. Her serum phosphate levels increased during treatment and she was diagnosed with hyperphosphataemia. She was treated with phosphate binders to maintain normal levels. The chemotherapy drugs were attributed to the development of hyperphosphataemia. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events reported, and the number of cases. Some of the adverse events mentioned include joint disorders, abdominal pain, alopecia, dizziness, fatigue, nausea, and skin disorders. It is important to note that this information is based on case reports and should be interpreted with caution. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events reported, and the number of cases. Some of the adverse events mentioned include joint disorders, abdominal pain, alopecia, dizziness, fatigue, nausea, and skin disorders. It is important to note that this information is based on case reports and should be interpreted with caution. [Extracted from the article]

A 32-year-old man with spindle/round cell sarcoma of the sinonasal tract exhibited lack of efficacy during treatment with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. Despite receiving chemotherapy and proton radiotherapy, he developed aphasia and meningeal sarcomatosis, indicating treatment failure. His condition worsened, leading to the insertion of a cerebral shunt, but he ultimately passed away due to increased intracranial pressure. [Extracted from the article]

A 76-year-old man with secondary haemophagocytic lymphohistiocytosis (sHLH) exhibited lack of efficacy during treatment with dexamethasone, immune-globulin, and etoposide. He was diagnosed with SARS-Cov-2 infection and admitted to the hospital after experiencing a recurrence of fever. Despite the initial treatment, his symptoms did not improve, leading to a change in therapy to ruxolitinib and methylprednisolone, which resulted in significant improvement after one week. [Extracted from the article]

The article from Reactions Weekly discusses a retrospective study involving 5 patients with solid pseudopapillary neoplasm (SPN) of the pancreas. Three adult patients were treated with gemcitabine plus gimeracil/oteracil/tegafur, etoposide, and everolimus for SPN but experienced lack of efficacy, as they all showed disease progression while on therapy. The patients initially underwent surgical resection before receiving chemotherapy, highlighting the challenges in treating SPN with these specific medications. [Extracted from the article]

A retrospective study of 24 patients with nasopharyngeal carcinoma found that some patients developed hyperthyroidism or experienced a lack of efficacy during treatment with bleomycin, epirubicin, cisplatin, ifosfamide, etoposide, and carboplatin. One patient developed hyperthyroidism as a result of the treatment, while another patient did not respond to the treatment and ultimately died from progressive nasopharyngeal carcinoma. The study does not provide information about the ages or genders of the patients, nor does it specify the routes, dosages, or duration of treatment that led to these reactions. [Extracted from the article]

A 47-year-old woman with large B-cell lymphoma developed cytomegalovirus colitis while receiving axicabtagene-ciloleucel treatment. She also experienced lack of efficacy during treatment with cyclophosphamide, doxorubicin, etoposide, prednisone, rituximab, and vincristine. After being refractory to the initial treatment, she received chimeric antigen receptor-T cell (CAR-T) therapy and developed haematochezia with haemodynamic instability. Colonoscopy revealed ulcers and active bleeding, and CMV immunostaining and viral load confirmed cytomegalovirus colitis. Treatment with ganciclovir improved her condition. [Extracted from the article]

In a retrospective study of 122 adults treated for primary mediastinal large B-cell lymphoma (PMBL), a patient exhibited lack of effectiveness during treatment with a combination of etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab. The patient initially received a cycle of the R-CHOP regimen, followed by five courses of the R-DA-EPOCH regimen. However, the disease progressed, indicating a lack of efficacy. The study highlights the need for further research and alternative treatment options for PMBL. [Extracted from the article]

In a case series involving two patients, a 14-year-old boy and a 9-year-old boy, both exhibited lack of efficacy during their respective cancer treatments. The first patient, who had a history of kidney transplant, initially received rituximab monotherapy for a large B-cell neoplasm but experienced disease progression. He then underwent chemoimmunotherapy with bortezomib, cyclophosphamide, dexamethasone, and daratumumab, but relapsed while on therapy. After further examination, he was diagnosed with posttransplant plasmablastic lymphoma and received EPOCH chemotherapy, achieving remission. The second patient, who had a history of heart transplant, underwent surgery for intestinal obstruction and was subsequently diagnosed with posttransplant plasmablastic lymphoma. He received EPOCH chemotherapy with bortezomib but unfortunately died due to lack of efficacy. [Extracted from the article]

A retrospective study was conducted on 78 patients with metastatic non-small cell lung cancer, and one patient was described who experienced a lack of efficacy during treatment with pembrolizumab. The patient's disease progressed despite receiving pembrolizumab, and they subsequently received second-line treatment with cisplatin and etoposide. The specific details regarding the patient's age, sex, and treatment outcomes were not provided in the article. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of carboplatin and etoposide in the treatment of primary hepatic neuroendocrine carcinoma in a 65-year-old man. The patient, who also had type 2 diabetes, initially presented with abdominal pain and was treated with piperacillin/tazobactam. After further examination, the diagnosis of primary hepatic neuroendocrine carcinoma was confirmed, and the patient began receiving carboplatin. He was later discharged from the hospital and prescribed etoposide. However, despite receiving both medications, the patient's condition worsened, and he ultimately died. [Extracted from the article]

In a retrospective study of 11 patients with diffuse large B-cell lymphoma (DLBCL), 10 patients experienced various toxicities during treatment with multiple drugs, including cyclophosphamide, doxorubicin, etoposide, prednisone, rituximab, venetoclax, and vincristine. The toxicities reported included neutropenia, febrile neutropenia, thrombocytopenia, anemia, sepsis, pulmonary infection, diarrhea, nausea, vomiting, and decreased fibrinogen. The study did not provide information on the patients' ages, sexes, duration of treatments, or outcomes. [Extracted from the article]

A 20-year-old man with no relevant medical history was diagnosed with primary brain alveolar rhabdomyosarcoma (ARMS) and underwent surgery. He then started chemotherapy with vincristine, dactinomycin, and cyclophosphamide, but serial MRI scans showed no shrinkage of the tumors. Radiotherapy and additional chemotherapy regimens were added, but there was still no therapeutic response, and the lesions continued to grow. The man eventually died from primary brain ARMS six months after surgery. The lack of efficacy was observed with the drugs vincristine, dactinomycin, cyclophosphamide, doxorubicin, ifosfamide, and etoposide. [Extracted from the article]

A case report published in Reactions Weekly describes a patient with Hodgkin's lymphoma who developed oesophageal perforation during treatment with etoposide and melphalan. The patient underwent autologous stem cell transplantation with a high dose of filgrastim, and subsequently experienced oesophageal perforation as a result of the etoposide and melphalan therapy. Unfortunately, the patient died due to this complication. This study, conducted between 1992 and 2022, highlights a serious adverse event associated with this treatment regimen. [Extracted from the article]

In a randomized prospective pilot study, a patient with non-small cell lung cancer developed bone marrow depression during treatment with cisplatin and etoposide. The patient underwent pulmonary resection and received chemotherapy followed by radiation therapy. However, the patient experienced bone marrow depression as a result of the treatment. The study does not provide specific details about the patient's age, sex, or the duration of treatment. [Extracted from the article]

This article presents four case reports of children aged 6-11 years who developed haematological toxicity while undergoing treatment for undifferentiated embryonal sarcoma of the liver (UESL). The patients received a combination of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. Despite the toxicity, all patients underwent complete resection of liver tumors and received additional treatments such as radiotherapy. Remission of UESL was observed in all cases, with varying durations of remission ranging from 9 to 26 months. [Extracted from the article]

A retrospective study examined the lack of efficacy of various drugs in the treatment of choriocarcinoma in two young boys. The first case involved a 10-month-old boy who underwent multiple treatments including methotrexate, vinblastine, bleomycin, cisplatin, doxorubicin, etoposide, and ifosfamide, but unfortunately passed away due to choriocarcinoma. The second case involved a 1-month-old boy who also received treatment with etoposide, ifosfamide, and cisplatin, but also passed away due to choriocarcinoma. These cases highlight the challenges in treating choriocarcinoma in young patients. [Extracted from the article]

In a retrospective study involving 35 patients treated for leptomeningeal metastasis (LM), three patients developed hydrocephalus, sensory neurological deficits, and seizures during treatment with etoposide. The patients had been diagnosed with LM and were receiving intra-CSF etoposide, with one patient also receiving three oral chemotherapy drugs. The specific dosages, duration of treatments, and outcomes of the adverse reactions were not provided. [Extracted from the article]

In a retrospective study of 63 elderly patients with extensive-stage small-cell lung cancer (ES-SCLC), two patients developed aspiration or gastrointestinal bleeding during treatment with carboplatin and etoposide. Both patients had a history of ES-SCLC and were receiving cyclic treatment with IV carboplatin and IV etoposide. Unfortunately, both patients died as a result of these adverse drug reactions. The study highlights the potential risks associated with this treatment regimen in elderly patients. [Extracted from the article]

In a retrospective study involving 92 patients with relapsed refractory lymphoma, three patients developed fungal pneumonia, nausea, or a transient ischemic attack while receiving treatment with prednisolone, etoposide, procarbazine, and cyclophosphamide (PEP-C). The patients had been diagnosed with relapsed refractory lymphoma and were receiving a specific treatment regimen. However, they experienced adverse reactions to the medication and subsequently discontinued the treatment. The study does not provide information on the outcomes of these reactions or the duration of treatment before the reactions occurred. [Extracted from the article]

A 56-year-old man with lung squamous cell carcinoma exhibited lack of efficacy during treatment with etoposide, cisplatin, and sugemalimab. He initially showed improvement in symptoms with sugemalimab, but later experienced progressive disease. Treatment with etoposide and cisplatin also did not effectively treat the disease, and the man eventually died from lung SCC. This case highlights the lack of efficacy of these medications for this particular patient. [Extracted from the article]

A 5-month-old girl developed sinusoidal obstructive syndrome and ototoxicity during treatment for an embryonal tumor with multilayered rosettes. She presented with vomiting and somnolence, and a brain MRI revealed a tumor in the right posterior fossa. After receiving induction chemotherapy, her tumor size decreased and she underwent surgery. However, she developed sinusoidal obstructive syndrome and was treated with defibrotide. She also developed ototoxicity and required hearing aids. At the age of 6, she was attending school. [Extracted from the article]

A retrospective study of 104 patients with neuroendocrine carcinoma (NEC) found that two patients developed elevated creatinine levels while receiving treatment with cisplatin and etoposide. The patients had a history of NEC and were receiving intravenous cisplatin and etoposide. Both patients experienced grade 3 elevated creatinine levels, with levels of 3.35 mg/dL and 3.88 mg/dL. The study did not provide information on the duration of treatment or the outcomes for these patients. [Extracted from the article]

A 31-year-old woman experienced peripheral neuropathy, nausea, and constipation while undergoing treatment for immature teratoma during pregnancy. She delivered a healthy baby girl and continued treatment post-partum. The woman underwent a laparoscopy to remove an ovarian cyst and was in remission 22 months after diagnosis. The child showed no signs of developmental delay or congenital abnormalities. [Extracted from the article]

In a retrospective study, 22 patients with glioblastoma were described as developing neutropenia or pulmonary embolism during off-label treatment with trofosfamide and etoposide. The specific dosages, routes, durations of treatments, and outcomes were not provided. It was noted that the patients received off-label treatment with trofosfamide and etoposide, but experienced neutropenia (n=1) and pulmonary embolism (n=1) as a result. [Extracted from the article]

A 72-year-old man developed a tracheomediastinal fistula while undergoing treatment for limited stage small cell lung cancer (SCLC) with cisplatin and etoposide. He also experienced a lack of efficacy with pegfilgrastim, a medication used to prevent febrile neutropenia. The man presented with symptoms such as blurred vision and dysphagia, and was diagnosed with SCLC and myasthenia gravis. Despite treatment with antibiotics and reduced dosages of cisplatin and etoposide, the man developed febrile neutropenia again and was found to have a life-threatening tracheomediastinal fistula. He was treated with antibiotics and his chemotherapy was discontinued, with no further recurrence of SCLC noted. Stent placement was considered to repair the fistula. [Extracted from the article]

A 66-year-old man developed febrile neutropenia while undergoing treatment with etoposide and cisplatin for bile duct mixed neuroendocrine-nonendocrine neoplasm. He experienced back pain and epicardial pain for 3 months before being diagnosed. The man received IV etoposide and cisplatin, with the dose of etoposide increasing in the second and third courses. After two courses, he developed grade 3 febrile neutropenia, but his neoplasm improved after the third course. The article does not mention the outcome of the adverse drug reaction. [Extracted from the article]

A retrospective study examined 56 patients with small cell lung cancer who were treated with a combination of cisplatin, etoposide, and catequentinib. The study found that some patients developed thrombocytopenia and hand and foot syndrome as a result of the treatment. Thrombocytopenia was observed in one patient from the control group, while hand and foot syndrome was observed in one patient from the treatment group. The study did not provide information on the ages or sexes of the patients, the duration of treatments, or the outcomes of the reactions. [Extracted from the article]